Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On June 27, 2024, X4 Pharmaceuticals, Inc. (XFOR) announced positive interim results from the company's ongoing Phase 2 trial of mavorixafor in patients with chronic neutropenia (CN).</li><li>The data showed that treatment with mavorixafor, as either a monotherapy or in combination with granulocyte colony-stimulating factor (G-CSF) was generally well tolerated and led to durable increases in patients' absolute neutrophil counts.</li><li>The company also announced that it has begun screening patients for enrollment into the Phase 3 clinical trial of mavorixafor in people with congenital, acquired primary immune, or idiopathic CN who are experiencing recurrent and/or serious infections.</li></ul>

On June 27, 2024, X4 Pharmaceuticals, Inc. (XFOR) announced positive interim results from the company's ongoing Phase 2 trial of mavorixafor in patients with chronic neutropenia (CN).The data showed that treatment with mavorixafor, as either a monotherapy or in combination with granulocyte colony-stimulating factor (G-CSF) was generally well tolerated and led to durable increases in patients' absolute neutrophil counts.The company also announced that it has begun screening patients for enrollment into the Phase 3 clinical trial of mavorixafor in people with congenital, acquired primary immune, or idiopathic CN who are experiencing recurrent and/or serious infections.

XFOR: Positive Interim Data from Ongoing Phase 2 Trial of Mavorixafor in Chronic Neutropenia Patients